Lyudmila Burdelya

Lyudmila Burdelya

PhD

About Me

Biography:

Dr. Burdelya earned her PhD in Experimental Oncology at the Blokhin Cancer Research Center in Moscow, Russia, and completed her postdoctoral research in Tumor Immunology at the Moffitt Cancer Center and Research Institute, Tampa, Florida. Before joining Roswell Park Comprehensive Cancer Center, she worked as a Research Associate in the Department of Molecular Genetics at The Cleveland Clinic Foundation, Cleveland, Ohio.

Dr. Burdelya is an active member of the American Association for Cancer Research and the Radiation Research Society. She is the author of over 20 peer-reviewed articles and numerous abstracts.

Currently, Dr. Burdelya’s research program is focused on the development and application of immune response modulators which act through TLR5 signaling for the prevention of normal tissue injury and reduction of adverse side effects induced by radiation and chemotherapeutic agents. Associated pre-clinical studies include the use of TLR5 agonists for anticancer therapy both alone or in combination with existing anti-cancer therapies.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Cell Stress Biology

Background

Education and Training:

  • PhD in Experimental Oncology from the Blokhin Cancer Research Center, Moscow, Russia
  • Postdoctoral research in Tumor Immunology at the Moffitt Cancer Center and Research Institute, Tampa, Florida

Professional Memberships:

  • American Association for Cancer Research
  • Radiation Research Society

Research

Research Overview:

  • Development of a new approach to anti-cancer therapy based on the activation of TLR5 signaling for the prevention of normal tissue injury and reduction of adverse side effects as may be induced by local irradiation or chemotherapeutic agents with dose-limiting toxicities.
  • Investigation of the mechanisms underlying the protection provided by TLR5 agonists.
  • Development of TLR5 agonists as potential anticancer therapeutic agents.
  • Development of a potent immunostimulatory anticancer therapy by the rational combination of TLR5 agonistic agents with existing anticancer therapies.

Publications

Burdelya LG, Brackett CM, Kojouharov BM, Gitlin II, Leonova K, Gleiberman AS, Aygun-Sunar S, Veith JM, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, Medvedev A, Scheblyakov D, Artemicheva NM, Logunov DY, Gintsburg AL, Naroditsky BS, Makarov SS, Gudkov AV. Central role of the liver in anticancer and radioprotective activities of toll-like receptor 5 agonists. Proc Natl Acad Sci USA, 2013, May 14; 110(20): 1857-66. PMID: 23630282.

Kojouharov BM, Brackett CM, Veith JM, Johnson CP, Gitlin II, Toshkov IA, Gleiberman AS, Gudkov AV, Burdelya LG. Toll-like receptor 5 agonist entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget, 2014, Mar 5; 1 (3). PMID: 24583651.

Yang H, Brackett CM, Morales-Tirado VM, Li Z, Zhang Q, Wilson MW, Benjamin C, Harris W, Waller EK, Gudkov AV, Burdelya LG, Grossniklaus HE. The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget, 2016, 7(3):2936-50. PMID: 26655090.

Toshkov IA, Gleiberman AS, Mett VL, Hutson AD, Singh AK, Gudkov AV, Burdelya LG. Mitigation of radiation-induced epithelial damage by the TLR5-agonist entolimod in a mouse model of fractionated head and neck irradiation. Radiat Res, 2017, May; 187(5):570-580. PMID: 28323577.